The Sunrise Podcast: Avoiding the Pain Points of Getting MedTech to Market, with Adam Jacobs

 

Getting a medical product to market is no simple task. From conception, to development, to marketing to appeal to audiences worldwide, every step has its speed bumps, and like a speed bump, and put in place for good measure. Quality control for feasibility and engineering tests both play a part in making sure that the product is functional, viable, and in many cases, FDA approved.

On today’s episode of The Sunrise Podcast, Adam Jacobs, Chief Technology Officer at Sunrise Labs, reeducates on how products are submitted and certified by the FDA and what kind of things need to be done during product development, including ISO 13485 certification for medical devices.

It’s a long and necessary process, especially when the product needs to be manufactured so that it’s reliable and economically sound for the consumer, but also profitable, and that’s where complications often come in. Many companies may work on a single product for long periods of time and end up not getting exposure, and everyone wants to “get to profitability as quickly as they can,” according to Jacobs.

“We probably have 20 or so projects at any given time, and as CTO I’m lucky and get to be exposed to most of them,” Jacobs said, which also means that he sees the products that weren’t put together well. “Getting a mature vision of what you want it to be is often one of the best things that you can do,” because otherwise medtech companies may have to change their products or production process downstream, an expensive and time-consuming mistake.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @HealthMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More